[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 102
1. Kasamon YL, Wahl RL: FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol; 2008 Mar;20(2):206-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.
  • PURPOSE OF REVIEW: The prognostic utility of midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography (F-FDG PET) has become widely appreciated in aggressive B-cell non-Hodgkin's lymphoma and, more recently, in Hodgkin's lymphoma.
  • How to tailor therapy based on the midtreatment PET result is the focus of current trials and is presently being defined for both Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2005 Jul;16(7):1160-8 [15939713.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4652-61 [15837965.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4643-51 [15837966.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4634-42 [15837968.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4574-6 [15837972.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1296-300 [16766583.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1267-73 [16883004.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):965-72 [16920563.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):759-67 [16871391.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10):1643-8 [17015900.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Nov;28(11):711-4 [17114956.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2678-87 [17063502.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:19S-27S [17204717.001]
  • [Cites] Blood. 2007 Jan 15;109(2):486-91 [17003382.001]
  • [Cites] Blood. 2007 Feb 1;109(3):905-9 [17018856.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Acad Radiol. 2007 Mar;14(3):330-9 [17307666.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):399-402 [16514616.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):338-46 [17400393.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2481-9 [17497648.001]
  • [Cites] Radiology. 2007 Jul;244(1):257-62 [17581905.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3746-52 [17646666.001]
  • [Cites] Nucl Med Commun. 2007 Oct;28(10):798-803 [17728610.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1361-9 [17623832.001]
  • [Cites] J Nucl Med. 2007 Oct;48(10):1626-32 [17873129.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Hematology. 2007 Oct;12(5):423-30 [17852456.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1185-9 [10586335.001]
  • [Cites] J Nucl Med. 2000 Jun;41(6):999-1005 [10855624.001]
  • [Cites] Haematologica. 2000 Jun;85(6):613-8 [10870118.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):543-53 [11342337.001]
  • [Cites] Leukemia. 2002 Feb;16(2):260-7 [11840293.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(2):103-11 [12132049.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1356-63 [12196360.001]
  • [Cites] J Nucl Med. 2003 Feb;44(2):170-6 [12571205.001]
  • [Cites] Blood. 2003 May 15;101(10):3875-6 [12531812.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S82-8 [12719922.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Chest. 2003 Aug;124(2):608-13 [12907550.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):282-7 [14531910.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1574-97 [14579100.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1304-15 [14607760.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):85-92 [15061202.001]
  • [Cites] Radiology. 2004 Sep;232(3):823-9 [15273335.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):38-45 [3806158.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Radiology. 1995 Jul;196(1):167-73 [7784562.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1290-7 [9113932.001]
  • [Cites] Radiology. 2005 Dec;237(3):1038-45 [16304117.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):544-8 [16446326.001]
  • [Cites] Haematologica. 2006 Apr;91(4):490-5 [16533726.001]
  • [Cites] Haematologica. 2006 Apr;91(4):475-81 [16585014.001]
  • [Cites] J Nucl Med. 2006 Apr;47(4):603-8 [16595493.001]
  • [Cites] Bone Marrow Transplant. 2006 Aug;38(3):211-6 [16770314.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):48-55 [9440722.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):173-80 [9440740.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4464-71 [9616140.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Cancer Chemother Rep. 1964 Feb;35:1-111 [14117037.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3483-9 [15315964.001]
  • [Cites] Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6 [15564152.001]
  • (PMID = 18300772.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124465-01A2; United States / NCI NIH HHS / CA / K23 CA124465; United States / NCI NIH HHS / CA / K23 CA124465-01A2
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 78
  • [Other-IDs] NLM/ NIHMS281899; NLM/ PMC3652336
  •  go-up   go-down


2. Pereg D, Koren G, Lishner M: The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy. Haematologica; 2007 Sep;92(9):1230-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy.
  • BACKGROUND AND OBJECTIVES: Lymphoma is the fourth most frequent malignancy diagnosed during pregnancy, occurring in approximately 1 over 6000 deliveries.
  • DESIGN AND METHODS: Its occurrence may increase due to the current trend to postpone pregnancy until later in life and the evidence suggested high incidence of AIDS-related non-Hodgkin's lymphoma in developing countries.
  • The relatively rare occurrence of pregnancy-associated lymphoma precludes the conduction of large, prospective studies to examine diagnostic, management and outcome issues.
  • In the vast majority of cases, when lymphoma is diagnosed during the first trimester, treatment with a standard chemotherapy regimen, following pregnancy termination should be recommended.
  • In the rare patients at low risk, such as those with stage 1 Hodgkin's lymphoma or indolent non-Hodgkins lymphoma, therapy can be delayed until the end of the first trimester and of embryogenesis while keeping the patients under close observation.
  • INTERPRETATION AND CONCLUSIONS: When lymphoma is diagnosed during the second and third trimesters, evidence exists suggesting that full-dose chemotherapy can be administered safely without apparent increased risk of severe adverse fetal outcome.
  • [MeSH-major] Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Pregnancy Complications, Neoplastic / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666365.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 67
  •  go-up   go-down


3. Rudant J, Menegaux F, Leverger G, Baruchel A, Nelken B, Bertrand Y, Hartmann O, Pacquement H, Vérité C, Robert A, Michel G, Margueritte G, Gandemer V, Hémon D, Clavel J: Family history of cancer in children with acute leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma: the ESCALE study (SFCE). Int J Cancer; 2007 Jul 1;121(1):119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history of cancer in children with acute leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma: the ESCALE study (SFCE).
  • A total of 773 cases of acute leukemia (AL), 130 of Hodgkin's lymphoma (HL), 163 of non-Hodgkin's lymphoma (NHL) and 1,681 population-based controls were included.
  • In conclusion, the study findings support the hypothesis of familial susceptibility to childhood lymphoma, but do not suggest familial susceptibility to childhood AL.
  • [MeSH-major] Hodgkin Disease / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330239.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Fitzgerald TJ, Bishop-Jodoin M, Cicchetti MG, Hanusik R, Kessel S, Laurie F, McCarten KM, Moni J, Pieters RS, Rosen N, Ulin K, Urie M, Chauvenet AR, Constine LS, Deye J, Vikram B, Friedman D, Marcus RB Jr, Mendenhall NP, Williams JL, Purdy J, Saltz J, Schwartz CL, White KS, Wolden S: Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: in regard to Bekelman and Yahalom (Int J Radiat Oncol Biol Phys 2009;73:492-498). Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):315-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: in regard to Bekelman and Yahalom (Int J Radiat Oncol Biol Phys 2009;73:492-498).

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):198-202 [16136581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S76-9 [18406943.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):492-8 [18804334.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2769-79 [9256118.001]
  • [Cites] Blood. 2009 Sep 3;114(10):2051-9 [19584400.001]
  • [Cites] J Digit Imaging. 2009 Mar;22(1):15-24 [17924166.001]
  • [CommentOn] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):492-8 [18804334.001]
  • (PMID = 20394859.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA029511-27; United States / NCI NIH HHS / CA / U10 CA029511-23; United States / NCI NIH HHS / CA / CA029511-21; United States / NCI NIH HHS / CA / U10 CA029511; United States / NCI NIH HHS / CA / U10 CA029511-22; United States / NCI NIH HHS / CA / U10 CA029511-30; United States / NCI NIH HHS / CA / CA029511-22; United States / NCI NIH HHS / CA / CA029511-25; United States / NCI NIH HHS / CA / U10 CA029511-25; United States / NCI NIH HHS / CA / CA029511-26; United States / NCI NIH HHS / CA / U10 CA029511-26; United States / NCI NIH HHS / CA / U10 CA029511-20; United States / NCI NIH HHS / CA / CA029511-24; United States / NCI NIH HHS / CA / U10 CA029511-29; United States / NCI NIH HHS / CA / CA029511-23; United States / NCI NIH HHS / CA / U10 CA029511-28; United States / NCI NIH HHS / CA / U10 CA029511-24; United States / NCI NIH HHS / CA / CA029511-20; United States / NCI NIH HHS / CA / U10 CA029511-21
  • [Publication-type] Comment; Letter; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS168800; NLM/ PMC2908913
  •  go-up   go-down


5. de Oliveira KB, Oda JM, Voltarelli JC, Nasser TF, Ono MA, Fujita TC, Matsuo T, Watanabe MA: CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. J Clin Lab Anal; 2009;23(6):387-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
  • The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/ stromal cell-derived factor-1 (SDF1)-3'A) in CXCL12/SDF1 gene was assessed in breast cancer, Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL), since the chemokine CXCL12, previously known as SDF1, and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis, and metastasis of different types of tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Chemokine CXCL12 / genetics. Hodgkin Disease / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927352.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL12
  •  go-up   go-down


6. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC: 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica; 2006 Apr;91(4):522-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.
  • Despite the increasing number of publications concerning 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for post-treatment evaluation of lymphoma and the increasing availability of this novel diagnostic modality, its exact role in response assessment after therapy is still unknown.
  • The aim of this study was to systematically review the literature regarding the diagnostic performance of dedicated FDG-PET in evaluation of first-line therapy of Hodgkin's disease and (aggressive) non-Hodgkin's lymphoma, and to calculate summary estimates of its sensitivity and specificity.
  • Pooled sensitivity and specificity for detection of residual disease in Hodgkin's lymphoma were 84% (95% CI 71-9192%) and 90% (95% CI 84-9394%), respectively.
  • For non-Hodgkin's lymphoma, pooled sensitivity and specificity were 72% (95% CI 61-82%), and 100% (95% CI 97-100%), respectively.
  • FDG-PET showed reasonable sensitivity and high specificity for evaluation of first-line therapy in Hodgkin's and in non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / diagnosis. Neoplasm, Residual / diagnosis. Positron-Emission Tomography / standards

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585017.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Bonnet C, Beguin Y, Fassotte MF, Seidel L, Luyckx F, Fillet G: Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Eur J Haematol; 2007 May;78(5):399-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
  • BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome.
  • PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis.
  • [MeSH-major] CA-125 Antigen / blood. Hodgkin Disease / blood. Lymphoma, Non-Hodgkin / blood

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419741.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


8. Daugherty SE, Pfeiffer RM, Mellemkjaer L, Hemminki K, Goldin LR: No evidence for anticipation in lymphoproliferative tumors in population-based samples. Cancer Epidemiol Biomarkers Prev; 2005 May;14(5):1245-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic anticipation in familial non-Hodgkin's lymphoma, Hodgkin's lymphoma, and chronic lymphocytic leukemia (CLL) has been consistently reported in the literature.
  • Our report investigates anticipation in four lymphoproliferative cancers, non-Hodgkin's lymphoma, Hodgkin's lymphoma, CLL, and multiple myeloma, drawn from Swedish and Danish population-based registries.
  • Whereas no anticipation was observed for Hodgkin's lymphoma, CLL, and multiple myeloma, our initial model, which controlled for gender and country, suggested a significant difference (hazard ratio, 0.5; 95% confidence interval, 0.33-0.75) in age at diagnosis between the parents and offspring in the non-Hodgkin's lymphoma sample.
  • However, once we accounted for the significant change in non-Hodgkin's lymphoma incidence over time, the statistical difference between parents and offspring disappeared (hazard ratio, 0.99; 95% confidence interval, 0.56-1.76).
  • [MeSH-major] Genetic Predisposition to Disease. Hodgkin Disease / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Multiple Myeloma / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894680.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Lim U, Morton LM, Subar AF, Baris D, Stolzenberg-Solomon R, Leitzmann M, Kipnis V, Mouw T, Carroll L, Schatzkin A, Hartge P: Alcohol, smoking, and body size in relation to incident Hodgkin's and non-Hodgkin's lymphoma risk. Am J Epidemiol; 2007 Sep 15;166(6):697-708
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol, smoking, and body size in relation to incident Hodgkin's and non-Hodgkin's lymphoma risk.
  • Studies associate alcohol consumption, cigarette smoking, and body size with the risk of overall or subtype lymphoma.
  • In the prospective National Institutes of Health-former American Association of Retired Persons (NIH-AARP) Diet and Health Study, the authors assessed the above lifestyle factors via baseline questionnaire among 285,079 men and 188,905 women aged 50-71 years and ascertained histologically confirmed Hodgkin's lymphoma (n = 58) and non-Hodgkin's lymphoma (n = 1,381) cases through linkage with cancer registries from 1995 to 2000.
  • Compared with nondrinkers, alcohol consumers had a lower risk for non-Hodgkin's lymphoma overall (for >28 drinks/week: adjusted relative risk (RR) = 0.77, 95% confidence interval (CI): 0.59, 1.00; p(trend) among drinkers = 0.02) and for its main subtypes.
  • Compared with never smokers, current smokers and recent quitters (<or=4 years ago) had higher risk of Hodgkin's lymphoma (RR = 2.25, 95% CI: 1.04, 4.89; RR = 4.20, 95% CI: 1.94, 9.09, respectively), whereas current or former smokers had lower risk of follicular non-Hodgkin's lymphoma (RR = 0.67, 95% CI: 0.52, 0.86).
  • Severe obesity (body mass index of >or=35: RR = 1.29, 95% CI: 1.02, 1.64) and taller height (RR = 1.19, 95% CI: 1.03, 1.38) were associated moderately with non-Hodgkin's lymphoma.
  • These findings add to the evidence that lifestyle factors and relevant anthropometric characteristics play a role in lymphoma etiology.
  • [MeSH-major] Alcohol Drinking / adverse effects. Body Size. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17596266.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


10. Coenegrachts K, Vanbeckevoort D, Deraedt K, Van Steenbergen W: Mri findings in primary non-Hodgkin's lymphoma of the liver. JBR-BTR; 2005 Jan-Feb;88(1):17-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mri findings in primary non-Hodgkin's lymphoma of the liver.
  • Primary lymphoma of the liver is a very rare malignancy.
  • Most often, these lesions consist of diffuse large B-cell non-Hodgkin's lymphoma that occurs mostly in immunodeficient patients.
  • Secondary liver involvement during Hodgkin's and non-Hodgkin's lymphoma is frequent.
  • The present case describes the MRI features of a primary lymphoma of the liver presenting as a solitary nodule.
  • The primary lymphoma presents as a T2-hyperintense homogeneous nodule, with a signal intensity comparable with the signal intensity of the spleen.
  • It remains uncertain whether the presence of the Gamna-Gandy bodies is associated with the liver lymphoma or with the underlying sickle cell anaemia, or with a combination of both.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792163.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


11. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA: Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J; 2005 Sep-Oct;11(5):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
  • This study assessed efficacy, optimal dosage and timing, and toxicity of involved-field radiotherapy used in conjunction with high-dose chemotherapy and stem cell transplantation for patients with refractory/relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS AND MATERIALS: 306 patients with refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma were analyzed.
  • The other 265 patients with refractory/relapsed non-Hodgkin's lymphoma and Hodgkin's disease received high-dose chemotherapy/stem cell transplantation, but not involved-field radiotherapy.
  • Multivariate analysis found that patients who did not receive involved-field radiotherapy were 2.09 times more likely to die during the follow-up period than patients who received involved-field radiotherapy (P = 0.066; adjusted for age, stem cell transplantation type, stage I/II vs stage III/IV, refractory vs relapsed, and Hodgkin's disease vs non-Hodgkin's lymphoma).
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259874.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Alexandrescu DT, Garino A, Brown-Balem KA, Wiernik PH: Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree. Leuk Lymphoma; 2006 Oct;47(10):2115-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree.
  • This study was conducted to determine whether anticipation occurs in families that exhibit both Hodgkin's (HD) and non-Hodgkin's (NHL) lymphoma in their pedigrees.
  • Nine published reports of multi-generational lymphoma and 33 previously unreported families with both lymphomas were analysed for evidence of anticipation.
  • In addition, this study reports four previously unpublished families with three generations of lymphoma in their pedigrees.
  • [MeSH-major] Age of Onset. Anticipation, Genetic. Hodgkin Disease / diagnosis. Hodgkin Disease / genetics. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Oct;47(10):2015-6 [17071471.001]
  • (PMID = 17071485.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E: Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann Oncol; 2005 Sep;16(9):1524-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
  • BACKGROUND: The aim of this study was to evaluate the accuracy of computed tomography (CT) and [(18)F]fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for prediction of progression-free survival of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) patients after completion of therapy.
  • FDG-PET suggested residual lymphoma in 24 patients.
  • CONCLUSIONS: Among lymphoma patients with PR and SD on CT, FDG-PET discriminated those destined to progress into a low risk of < or =20% and a high risk for recurrence of > or =80%.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946979.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O: FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol; 2006 Nov;85(11):759-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
  • Early therapy response assessment with metabolic imaging is potentially useful to determine prognosis in aggressive lymphoma and, thus, can guide first-line therapy.
  • Forty-eight patients with aggressive lymphoma [24 Hodgkin's disease (HD); 24 non-Hodgkin's lymphoma (NHL)] underwent fluoro-deoxyglucose positron emission tomography (FDG-PET) before chemotherapy (PET1) and at mid-treatment (PET2).
  • FDG-PET at mid-treatment can predict the outcome of patients with aggressive lymphoma and should be a useful tool to modify an ineffective therapy.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Positron-Emission Tomography / methods. Predictive Value of Tests. Tomography, Emission-Computed / methods

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871391.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


15. Albitar M, Vose JM, Johnson MM, Do KA, Day A, Jilani I, Kantarjian H, Keating M, O'Brien SM, Verstovsek S, Armitage JO, Giles FJ: Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res; 2007 Feb;31(2):139-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
  • Plasma levels of beta-2 microglobulin (beta2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
  • [MeSH-major] Biomarkers, Tumor / blood. HLA Antigens / blood. Hodgkin Disease / blood. Lymphoma, Non-Hodgkin / blood. beta 2-Microglobulin / blood

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2007 Feb;31(2):121-5 [16860865.001]
  • (PMID = 16545870.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / beta 2-Microglobulin
  •  go-up   go-down


16. Bekelman JE, Yahalom J: Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic review. Int J Radiat Oncol Biol Phys; 2009 Feb 1;73(2):492-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic review.
  • Although radiotherapy (RT) is an important component of curative therapy for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), we postulated that RT reporting may be inadequate in Phase III HL and NHL trials.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Publishing / standards. Radiation Oncology / standards. Randomized Controlled Trials as Topic / standards

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):315-6 [20394859.001]
  • (PMID = 18804334.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


17. Pinheiro KV, Hungria VT, Ficker ES, Valduga CJ, Mesquita CH, Maranhão RC: Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother Pharmacol; 2006 May;57(5):624-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE.
  • PATIENTS AND METHODS: The LDE labeled with [(3) H]-cholesteryl oleate was injected into four Hodgkin's and 12 non-Hodgkin's lymphoma patients and into 16 healthy control subjects and the LDE plasma residence time (RT) was determined from sequential plasma samples.
  • Two volunteers with relapsed/refractory lymphoma were treated with 300 mg/m(2) body surface etoposide associated with LDE in six cycles at 3-week intervals.
  • RESULTS: The LDL cholesterol was lower in lymphoma patients than in controls (94+/-52 and 115+/-16 mg/dL, p=0.0362, respectively).
  • The LDE RT was 49% smaller in lymphoma patients than in controls (RT=21.9 and 45.7 h; p=0.0134), with positive correlation between RT and LDL cholesterol.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / toxicity. Cholesterol Esters / pharmacokinetics. Etoposide / toxicity. Hodgkin Disease / metabolism. Lymphoma, Non-Hodgkin / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133527.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cholesterol Esters; 0 / Cholesterol, LDL; 0 / Drug Carriers; 0 / Emulsions; 0 / Receptors, LDL; 3DPK9KFN2M / cholesteryl oleate; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


18. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G: AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant; 2008 Feb;41(4):331-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
  • AMD3100 given with G-CSF has been shown to mobilize CD34+ cells in non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), and Hodgkin's disease (HD) patients who could not collect sufficient cells for autologous transplant following other mobilization regimens.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17994119.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Colony-Stimulating Factors; 0 / Heterocyclic Compounds; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 155148-31-5 / JM 3100
  •  go-up   go-down


19. MacDonald S, Bernard S, Balogh A, Spencer D, Sawchuk S: Electronic compensation using multileaf collimation for involved field radiation to the neck and mediastinum in non-Hodgkin's lymphoma and Hodgkin's lymphoma. Med Dosim; 2005;30(2):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electronic compensation using multileaf collimation for involved field radiation to the neck and mediastinum in non-Hodgkin's lymphoma and Hodgkin's lymphoma.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Hodgkin Disease / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Mediastinal Neoplasms / radiotherapy. Radiotherapy, Conformal / instrumentation

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922170.001).
  • [ISSN] 0958-3947
  • [Journal-full-title] Medical dosimetry : official journal of the American Association of Medical Dosimetrists
  • [ISO-abbreviation] Med Dosim
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Kostakoglu L: Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging; 2008 Aug;35(8):1413-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Outcome Assessment (Health Care) / methods. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18385996.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Altintas A, Cil T, Pasa S, Danis R, Kilinc I, Ayyildiz O, Muftuoglu E: Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience. Minerva Med; 2008 Feb;99(1):7-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience.
  • AIM: There is an increased risk of lymphoma subsequent to autoimmune conditions.
  • In this study, the association of autoimmunity and related autoantibodies within non-Hodgkin's (NHL) and Hodgkin's lymphoma (HL) patients has been investigated.
  • Afterwards, the results between the two lymphoma groups have been confronted.
  • CONCLUSION: In conclusion, ANA and related autoantibodies can frequently be detected during lymphoma treatment.
  • However, the majority of lymphoma patients with positive ANA did not display autoimmune diseases, demonstrating the lack of a strict correlation between the presence of ANA and autoimmune diseases.
  • [MeSH-major] Antibodies, Antinuclear / blood. Autoimmune Diseases / diagnosis. Hodgkin Disease / immunology. Lymphoma, Non-Hodgkin / immunology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Minerva Med. 2008 Aug;99(4):417 [18663350.001]
  • (PMID = 18299692.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Autoantigens; 0 / Biomarkers; 0 / Jo-1 antibody; 0 / Nuclear Proteins; 0 / Ribonucleoproteins, Small Nuclear; 0 / Scl 70 antigen, human; 0 / snRNP Core Proteins; EC 3.1.- / Exoribonucleases; EC 3.1.- / Exosome Multienzyme Ribonuclease Complex; EC 3.1.13.- / EXOSC10 protein, human
  •  go-up   go-down


22. Berrutti M, Pellicano R, Rizzetto M: One question on the work on antinuclear antibody levels in patients with Hodgkin's and non-Hodgkin's lymphoma. Minerva Med; 2008 Aug;99(4):417
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One question on the work on antinuclear antibody levels in patients with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / microbiology. Lymphoma, Non-Hodgkin / microbiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Minerva Med. 2008 Feb;99(1):7-14 [18299692.001]
  • (PMID = 18663350.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear
  •  go-up   go-down


23. Flinn IW, Berdeja JG: Blood and bone marrow transplantation for patients with Hodgkin's and non-Hodgkin's lymphoma. Cancer Treat Res; 2006;131:251-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood and bone marrow transplantation for patients with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Blood Transfusion. Bone Marrow Transplantation. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy


24. Okada S: [Recent advances in the treatment of AIDS-related malignant lymphoma]. Nihon Rinsho; 2010 Mar;68(3):491-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent advances in the treatment of AIDS-related malignant lymphoma].
  • The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • However, the number of HIV-associated non-Hodgkin's lymphoma patients has increased with the increase of HIV-1 infected patients in Japan.
  • Although the evidence currently supports an intensive and curative approach for the management of HIV-associated lymphoma, we must be vigilant about adverse effects and interaction of chemotherapeutic drugs, implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20229796.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 29
  •  go-up   go-down


25. Wedgwood A, Pro B, Younes A: The lymphomas: molecular pathways and novel therapeutic targets. Curr Hematol Rep; 2005 Jul;4(4):324-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review, we focus on new molecular targets that are currently being explored for the treatment of non-Hodgkin's lymphoma and Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009048.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD80; 0 / Antigens, Neoplasm; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 105
  •  go-up   go-down


26. Noy A: Update on HIV lymphoma. Curr Oncol Rep; 2007 Sep;9(5):384-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on HIV lymphoma.
  • In these countries, lymphoma is the most common HIV-associated malignancy.
  • The majority of investigation has been in diffuse large B cell lymphoma, with infusional therapy remaining promising but cumbersome.
  • Biologic insights have been attained in the spectrum of HIV-associated non-Hodgkin's lymphoma, Hodgkin's lymphoma, and virologic coinfections.
  • Overall, the outcome for non-Hodgkin's lymphoma and Hodgkin's lymphoma in the setting of HIV continues to improve as insights into the pathophysiology and treatment advance.
  • [MeSH-major] Lymphoma, AIDS-Related

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706167.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 52
  •  go-up   go-down


27. Noy A: Update in HIV lymphoma. Curr Opin Oncol; 2006 Sep;18(5):449-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update in HIV lymphoma.
  • Lymphoma is the most common HIV-associated malignancy in these countries.
  • RECENT FINDINGS: Investigators continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, even in the era of highly active antiretroviral therapy.
  • The majority of work has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising, and rituximab an area of investigation.
  • Biological insights have been gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virological co-infections.
  • SUMMARY: The outcome for individuals infected with HIV and developing non-Hodgkin's lymphoma and Hodgkin's disease continues to improve as insights into the pathophysiology and treatment advance.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894292.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 45
  •  go-up   go-down


28. Goodman KA, Toner S, Hunt M, Wu EJ, Yahalom J: Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys; 2005 May 1;62(1):198-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy for lymphoma involving the mediastinum.
  • PURPOSE: To determine the feasibility, potential advantage, and indications for intensity-modulated radiotherapy (IMRT) in the treatment of Hodgkin's lymphoma or non-Hodgkin's lymphoma involving excessively large mediastinal disease volumes or requiring repeat RT.
  • METHODS AND MATERIALS: Sixteen patients with Hodgkin's lymphoma (n = 11) or non-Hodgkin's lymphoma (n = 5) undergoing primary radiotherapy or repeat RT delivered via an IMRT plan were studied.
  • CONCLUSION: In selected patients with Hodgkin's lymphoma and non-Hodgkin's lymphoma involving the mediastinum, IMRT provides improved planning target volume coverage and reduces pulmonary toxicity parameters.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Mediastinal Neoplasms / radiotherapy. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850922.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Younes A: Angiogenesis in lymphoma: a short review. Curr Mol Med; 2005 Nov;5(7):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis in lymphoma: a short review.
  • This short review focuses on recent advances in angiogenesis-research in non-Hodgkin's lymphoma and Hodgkin's disease.
  • [MeSH-major] Lymphoma / physiopathology. Neovascularization, Pathologic
  • [MeSH-minor] Animals. Hodgkin Disease / physiopathology. Humans. Lymphoma, Non-Hodgkin / physiopathology. Vascular Endothelial Growth Factors / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16305487.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factors
  • [Number-of-references] 28
  •  go-up   go-down


30. Taylor MD, Jones DR: Genetic markers of mediastinal tumors. Thorac Surg Clin; 2009 Feb;19(1):17-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These new techniques have enabled scientists to uncover differential gene expression patterns between subtypes of thymomas, correlate tumor marker expression with germ cell tumors, and determine a link between the NF-kappaB and JAK/STAT pathways with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chromosome Aberrations. Humans. Lymphoma / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Neoplasms, Nerve Tissue / genetics. Thymoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288817.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Number-of-references] 47
  •  go-up   go-down


31. Read D, Wright C, Weinstein P, Borman B: Cancer incidence and mortality in a New Zealand community potentially exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin from 2,4,5-trichlorophenoxyacetic acid manufacture. Aust N Z J Public Health; 2007 Feb;31(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate whether the rates of all cancers and four cancers (soft tissue sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease and chronic lymphocytic leukaemia) associated with dioxin exposure are higher in New Plymouth, the site of a former 2,4,5-T manufacturing plant, than for the rest of New Zealand.
  • For 1970-74, there was an elevated risk for all cancer incidence (SIR = 111, 95% CI 104-119), and for two of the four specific cancers that are associated with dioxin exposure (non-Hodgkin's lymphoma SIR = 175, 95% CI 121-246 and chronic lymphocytic leukaemia SIR = 251, 95% CI 144-408).

  • MedlinePlus Health Information. consumer health - Cancer.
  • Hazardous Substances Data Bank. 2,4,5-T .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333602.001).
  • [ISSN] 1326-0200
  • [Journal-full-title] Australian and New Zealand journal of public health
  • [ISO-abbreviation] Aust N Z J Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; 9Q963S4YMX / 2,4,5-Trichlorophenoxyacetic Acid; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


32. Sparano JA: HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol; 2007 Sep;19(5):458-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated lymphoma: the evidence for treating aggressively but with caution.
  • PURPOSE OF THE REVIEW: The aim of this article is to review key reports regarding the biology and management of HIV-associated lymphoma during the past year.
  • RECENT FINDINGS: The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, a stable or slightly increased risk of Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.
  • Emerging evidence suggests that patients with HIV-associated lymphoma should be treated in a similar manner as immunocompetent patients with the same disease, especially if the CD4 count is 50-100 cells/mul or higher.
  • Use of the anti-CD20 monoclonal antibody rituximab in combination with chemotherapy appears to result in improved control of B-cell lymphoma, but may come at the expense of an increased risk of bacterial and viral infections.
  • SUMMARY: Although the evidence currently supports an aggressive and curative approach for the management of HIV-associated lymphoma, clinicians must be vigilant about implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
  • [MeSH-major] HIV. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy


33. Cil T, Altintaş A, Işikdoğan A, Paşa S, Bayan K, Batun S, Büyükbayram H: Screening for Celiac disease in Hodgkin and non-Hodgkin lymphoma patients. Turk J Gastroenterol; 2009 Jun;20(2):87-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for Celiac disease in Hodgkin and non-Hodgkin lymphoma patients.
  • The aim of our prospective study was to evaluate the frequency of Celiac disease in patients with lymphoma and to determine the usefulness of the anti-gliadin and anti-endomysial antibodies (EMA) for diagnosis of Celiac disease in this patient group.
  • METHODS: We studied 119 patients with previously or newly diagnosed non-Hodgkin's lymphoma and 60 patients with Hodgkin's lymphoma who presented at the hematology and medical oncology divisions of Dicle University Hospital in Turkey between December 2002 and January 2006.
  • RESULTS: In the Hodgkin's lymphoma group, anti-gliadin immunoglobulin A was detected in 9 (15%) patients (3 male, 6 female), and antigliadin immunoglobulin G was detected in 21 (35%) patients (15 male, 6 female).
  • In the non-Hodgkin's lymphoma group, antigliadin immunoglobulin A was detected in 6 (5%) patients (2 M male 4 female), and anti-gliadin immunoglobulin G was detected in 30 (25.2%) patients (18 male, 12 female).
  • EMA immunoglobulin A and immunoglobulin G were not detected in the Hodgkin's lymphoma and non-Hodgkin's lymphoma groups.
  • CONCLUSIONS: Our report is the first to describe the frequency of Celiac disease in patients with lymphoma in the southeast region of Turkey.
  • In our study, there was no evidence that Celiac disease is a pre-malignant condition for lymphoma.
  • Serological screening for Celiac disease in lymphoma patients does not seem to be necessary.
  • [MeSH-major] Celiac Disease / epidemiology. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology


34. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, Alavi A: Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun; 2006 Jan;27(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?
  • OBJECTIVES: To assess the usefulness of [18F]fluorodeoxyglucose positron emission tomography in the detection of bone marrow involvement in malignant lymphoma, and its impact in clinical management.
  • METHODS: One hundred and six consecutive patients with a confirmed diagnosis of lymphoma, referred for staging or restaging of Hodgkin's lymphoma (n=18) or non-Hodgkin's lymphoma (n=88), were reviewed retrospectively.
  • The assessment of bone marrow involvement by lymphoma was confirmed by histology and/or progression of bone marrow lesions in clinical follow-up.
  • Ten cases of non-Hodgkin's lymphoma and two cases of Hodgkin's lymphoma with positive positron emission tomography results and an initial negative bone marrow biopsy showed clinical progression of the bone marrow lesions and/or subsequent positive histology.
  • In four cases of follicular lymphoma, the bone marrow biopsy was positive and the positron emission tomography scan was normal.
  • CONCLUSIONS: Positron emission tomography and bone marrow biopsy are complementary in assessing the presence of bone marrow involvement in patients with malignant lymphoma.
  • In our series, positron emission tomography was more sensitive than bone marrow biopsy in Hodgkin's and non-Hodgkin's lymphoma, except in follicular lymphoma.
  • [MeSH-major] Biopsy, Needle / methods. Bone Marrow / pathology. Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18. Ilium / pathology. Lymphoma / pathology. Lymphoma / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340718.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hodgkin's and non-Hodgkin's lymphoma are still problematic in patients with advanced disease with high viral loads.
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


36. Wedgwood A, Younes A: Targeting lymphoma cells and their microenvironment with novel antibodies. Clin Lymphoma Myeloma; 2006 Oct;7 Suppl 1:S33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting lymphoma cells and their microenvironment with novel antibodies.
  • Novel monoclonal antibodies are currently being evaluated and have been shown to have significantly influenced the treatment of Hodgkin's and non-Hodgkin's lymphoma.
  • It is of the utmost importance to reduce treatment-related toxicity and, hopefully, improve the cure rate of lymphoma.
  • Continued investigation is encouraged to combine monoclonal antibodies with other targeted therapies and incorporate their use into standards of care in the treatment of lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma / immunology. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101071.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20
  • [Number-of-references] 92
  •  go-up   go-down


37. Barr P, Fisher R, Friedberg J: The role of bortezomib in the treatment of lymphoma. Cancer Invest; 2007 Dec;25(8):766-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of bortezomib in the treatment of lymphoma.
  • Among the various cancers susceptible to proteasome inhibition are the non-Hodgkin's lymphomas.
  • Mantle cell lymphoma appears to be particularly sensitive, leading to the FDA approval of bortezomib in patients who have received at least one prior therapy.
  • In this review, we will detail the clinical results and ongoing trials utilizing bortezomib in Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma / drug therapy. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use
  • [MeSH-minor] Bortezomib. Hodgkin Disease / drug therapy. Humans. Lymphoma, Mantle-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058474.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 86
  •  go-up   go-down


38. Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA: Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med; 2008 Feb;22(2):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
  • OBJECTIVE: The objective of this study was to evaluate the prevalence and positron emission tomography (PET) imaging features of pulmonary drug toxicity in patients with lymphoma during or just following chemotherapy.
  • METHODS: A total of 677 PET scans on 460 patients with lymphoma (351 non-Hodgkin's lymphoma, 92 Hodgkin's disease, and 17 both Hodgkin's and non-Hodgkin's lymphoma) were performed for the evaluation of chemotherapy response.
  • Inclusion criteria of probable drug toxicity were abnormal but symmetrical FDG accumulation in both lungs seen during or just following the completion of chemotherapy, the abnormal accumulation or corresponding abnormal CT findings resolved on subsequent studies, exclusion of clinical diagnosis of pneumonia, radiation pneumonitis, or lymphoma involvement.
  • CONCLUSIONS: Diffuse and peripheral-dominant FDG accumulation in the lung, which may represent pulmonary drug toxicity, was not uncommon in patients with lymphoma who underwent chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Drug-Related Side Effects and Adverse Reactions / radionuclide imaging. Lung / drug effects. Lung / radionuclide imaging. Lymphoma / drug therapy. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311535.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


39. Koc F, Paydas S, Yerdelen D, Demirkiran M: Motor neuron disease associated with multiple myeloma. Int J Neurosci; 2008 Mar;118(3):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The association between Amyotrophic Lateral Sclerosis or other Motor Neuron Diseases (MNDs) with Lymphoproliferative Disorders (LPDs) and plasma cell neoplasias (such as Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, multiple myeloma, chronic lymphocytic leukemia) has been described.

  • Genetic Alliance. consumer health - Motor neuron disease.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300006.001).
  • [ISSN] 0020-7454
  • [Journal-full-title] The International journal of neuroscience
  • [ISO-abbreviation] Int. J. Neurosci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 7LJ087RS6F / Riluzole
  •  go-up   go-down


40. Ru YX, Eyden B, Li QH, Mao BY, Liu EB, Pang TX: Myofibroblast transformation in metastatic extramedullary chronic myeloid leukemia: a case report. Ultrastruct Pathol; 2009;33(3):136-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In non-Hodgkin's lymphoma, Hodgkin's disease, and leukemia, myofibroblasts are rather rarely documented.


41. Samaras P, Buset EM, Siciliano RD, Haile SR, Petrausch U, Mischo A, Honegger H, Pestalozzi BC, Schanz U, Stussi G, Stahel RA, Knuth A, Renner C, Stenner-Liewen F: Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology; 2010;79(1-2):93-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
  • OBJECTIVE: To evaluate the impact of pegfilgrastim on engraftment, hospital stay and resources in patients with Hodgkin's and non-Hodgkin's lymphoma after conditioning with high-dose BEAM followed by autologous peripheral blood stem cell transplantation (APBSCT) compared with filgrastim.
  • RESULTS: Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed.
  • CONCLUSION: Pegfilgrastim appears to be equivalent to filgrastim after high-dose BEAM followed by APBSCT in the treatment of lymphoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Granulocyte Colony-Stimulating Factor / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / drug therapy. Peripheral Blood Stem Cell Transplantation. Thrombocytopenia / drug therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21079406.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; L36H50F353 / Podophyllotoxin; PVI5M0M1GW / Filgrastim; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


42. Acikel CH, Kir T, Komurcu S, Kilic S, Ozett A, Rzayev M, Arpaci F, Ozturk B, Ogur R, Ataergin S, Kuzhan O, Hasde M: Some sociodemographic and diagnostic characteristics of military patients treated in the Department of Medical Oncology, Gülhane Military Medical Academy. Mil Med; 2006 May;171(5):420-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the study group, the five most common diagnoses were lung cancer, colorectal cancer, testicular cancer, non-Hodgkin's lymphoma, and Hodgkin's disease.
  • Although the first three diagnoses among officers were lung cancer, testicular cancer, and Hodgkin's disease, those among retired officers were colorectal cancer, lung cancer, and prostate cancer.
  • Among noncommissioned officers, the first three diagnoses were colorectal cancer, testicular cancer, and Hodgkin's disease for active duty patients and lung cancer, colorectal cancer, and gastric cancer for retired patients.
  • In the group of privates, testicular cancer, Hodgkin's disease, and non-Hodgkin's lymphoma were the first three diagnoses.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761893.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Ries F, Ferster A, Rieux-Laucat F, Biwer A, Dicato M: Autoimmune lymphoproliferative syndrome (ALPS). Case report and family history. Bull Soc Sci Med Grand Duche Luxemb; 2010;(2):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune lymphoproliferative syndrome (ALPS) is a rare disease caused by defective lymphocyte apoptosis and is characterized by non-malignant lymphoproliferation, hepatosplenomegaly, autoimmune manifestations and increased risk of both Hodgkin's and non-Hodgkin's lymphoma.

  • Genetic Alliance. consumer health - Autoimmune Lymphoproliferative Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882745.001).
  • [ISSN] 0037-9247
  • [Journal-full-title] Bulletin de la Société des sciences médicales du Grand-Duché de Luxembourg
  • [ISO-abbreviation] Bull Soc Sci Med Grand Duche Luxemb
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Luxembourg
  •  go-up   go-down


44. Fotiadis C, Georgopoulos I, Stoidis C, Patapis P: Primary tumors of the spleen. Int J Biomed Sci; 2009 Jun;5(2):85-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lymphoid tumors include Hodgkin's and non Hodgkin's lymphoma, histiocytic lymphoma and plasmacytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23675122.001).
  • [ISSN] 1550-9702
  • [Journal-full-title] International journal of biomedical science : IJBS
  • [ISO-abbreviation] Int J Biomed Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3614769
  • [Keywords] NOTNLM ; metastatic / primary / spleen / tumors
  •  go-up   go-down


45. O'Connor OA: Developing new drugs for the treatment of lymphoma. Eur J Haematol Suppl; 2005 Jul;(66):150-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing new drugs for the treatment of lymphoma.
  • Despite the great progress that has been made over the last several decades in the treatment of lymphoma, the prognosis for patients with relapsed disease, and particular sub-types of lymphoma like mantle cell and T cell lymphoma, remains quite poor.
  • While major advances in the use of combination chemotherapy, monoclonal antibodies, peripheral blood stem cell transplants, and radioimmunotherapy, have provided new opportunities to alter the natural history of these diseases, and even improve cure rates among elected sub-populations of patients, these 'traditional' approaches have not benefited all patients, or subtypes of lymphoma.
  • The incredibly rapid pace of understanding the molecular basis for the discrete sub-types of both non-Hodgkin's lymphoma and Hodgkin's Disease is beginning to afford exciting new opportunities to both risk stratify patients, and to identify potentially novel 'drugable' targets.
  • These advancements in understanding the major molecular defects in lymphoma, have provided a new context in which we can rethink the use of new and old drugs, and design new ones with unique mechanisms of action.
  • The panoply of new targets and drugs now becoming available for the treatment of lymphoma is truly daunting.
  • In many cases, the empirical observations from early clinical trials have provided invaluable clues to potentially valuable drugs like bortezomib, depsipeptide, and SAHA, These empirical observations, based on the inclusion of patients with lymphoma on these studies, have thus far proven to be as or more valuable than any other 'rational' target based approach.
  • While it would not be possible to address each and every new such drug, we hope to touch on some of the major new themes and agents emerging for the treatment of Hodgkin's Disease and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007885.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA 69913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 41
  •  go-up   go-down


46. Völk M, Strotzer M: [Diagnostic imaging of splenic disease]. Radiologe; 2006 Mar;46(3):229-43; quiz 244
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma represents the most common primary benign tumor, and lymphoma the most common primary malignant tumor of the spleen.
  • Diagnostic imaging does not a allow safe differentiation between Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16435091.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 24
  •  go-up   go-down


47. Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, Iravani M, Bahar B, Khodabandeh A, Khatami F, Ghaffari F, Jalali A: Stem cell transplantation; Iranian experience. Arch Iran Med; 2009 Jan;12(1):69-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cell transplantation was performed for various diseases including acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphoblastic leukemia, thalassemia major, sickle cell thalassemia, sickle cell disease, multiple myeloma, myelodysplasia, mucopolysaccharidosis, paroxysmal nocturnal hemoglobinuria, non-Hodgkin's lymphoma, Hodgkin's disease, severe aplastic anemia, plasma cell leukemia, Niemann-Pick disease, Fanconi anemia, severe combine immunodeficiency, congenital neutropenia, leukocyte adhesion deficiencies, Chediak-Higashi syndrome, osteopetrosis, histiocytosis X, Hurler syndrome, amyloidosis, systemic sclerosis, breast cancer, Ewing's sarcoma, testicular cancer, germ cell tumors, neuroblastoma, medulloblastoma, renal cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, Wilms' tumor, rhabdomyosarcoma, pancreatoblastoma, and multiple sclerosis.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Iran Med. 2009 May;12(3):329. Alimogaddam, Kamran [corrected to Alimoghaddam, Kamran]; Mousavi, Seyed Asadollah [corrected to Mousavi, Seied Asadollah]
  • [ErratumIn] Arch Iran Med. 2012 Aug;15(8):524
  • (PMID = 19111033.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


48. Jantunen E, Kuittinen T: Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues. Eur J Haematol; 2008 Apr;80(4):287-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While mobilization is usually easy and straightforward in patients with MM, about 10-20% of patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma are hard-to-mobilize.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182078.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 74
  •  go-up   go-down


49. Jardin F: Development of autoimmunity in lymphoma. Expert Rev Clin Immunol; 2008 Mar;4(2):247-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of autoimmunity in lymphoma.
  • Conversely, development of clinical or biological signs of autoimmunity at the time of the diagnosis of lymphoma or during its course indicates that lymphoma and autoimmune manifestations may constitute two faces of the same process.
  • The aim of this review is to describe autoimmune manifestations related to non-Hodgkin's lymphoma and Hodgkin's lymphoma, their specificity according to the lymphoma subtype and their physiopathological signification.
  • Lymphoma-related autoimmune manifestations include mainly skin diseases, hematological manifestations, rheumatic diseases and renal lesions.
  • Despite the lack of studies providing a systematic prospective assessment, autoimmune manifestations are observed in all lymphoma subtypes and seem particularly prevalent in marginal-zone lymphoma and T-cell lymphoma.
  • Monoclonal antibodies (including rituximab, Campath-1H or epratuzumab) constitute the most promising approach to treat lymphoma-related immune disorders.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477054.001).
  • [ISSN] 1744-8409
  • [Journal-full-title] Expert review of clinical immunology
  • [ISO-abbreviation] Expert Rev Clin Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Wannesson L, Panzarella T, Mikhael J, Keating A: Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Ann Oncol; 2007 Apr;18(4):623-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only two cases of graft failure (0.36%) occurred among 560 assessable patients receiving high-dose therapy and autotransplant for non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, germ-cell tumors and acute leukemias.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355952.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 51
  •  go-up   go-down


51. Pagano L, Caira M, Nosari A, Rossi G, Locatelli F, Viale P, Aversa F, Hema E-Chart Group Italy: Hema e-Chart: Italian Registry for prospective analysis of epidemiology, management and outcome of febrile events in patients with hematological malignancies. J Chemother; 2010 Feb;22(1):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its aim is to improve the speed, quality and integration of information related to subjects with febrile event, ultimately resulting in improving patients' care.Patients included adults and children with acute and chronic myeloid or lymphoid leukemia, Hodgkin's and non-Hodgkin's lymphoma, myelodysplastic syndrome, or multiple myeloma.

  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20227988.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Investigator] Levis A; Leoni P; Liso V; Baccarani M; Cortellazzo S; Rossi G; Russo D; La Nasa G; Storti S; Giustolisi R; Morabito F; Cuneo A; Bosi A; Capalbo SF; Cascavilla N; Ghio R; Carella A; Brugiatelli M; Ciceri F; Martinelli G; Morra E; Pogliani E; Mettivier V; Carli M; Abbadessa V; Musso M; Aricò M; Lazzarino M; Visani G; Fioritoni G; Di Bartolomeo P; Vallisa D; Petrini M; Favre C; Olivieri A; Gugliotta L; Leone G; Amadori S; De Rossi G; De Fabritiis P; Majolino I; D'Arco A; Lauria F; Mazza P; Fagioli F; Gherlinzoni F; Chesesi T; Rodeghiero F
  •  go-up   go-down


52. Ji J, Hemminki K: Familial blood vessel tumors and subsequent cancers. Ann Oncol; 2007 Jul;18(7):1260-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second Kaposi's sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease and myeloma were increased following primary skin Kaposi's sarcoma.

  • MedlinePlus Health Information. consumer health - Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17426058.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Piura B, Rabinovich A, Shaco-Levy R, Sukenik S: Vulvar invasive squamous cell carcinoma occurring in a young woman with systemic lupus erythematosus. Eur J Gynaecol Oncol; 2005;26(1):103-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although several studies have demonstrated a possible relationship between systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia and several solid tumors, it is still debatable whether SLE patients have an increased incidence of cancer overall.


54. Grant WB: Hypothesis--ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. Photochem Photobiol; 2008 Mar-Apr;84(2):356-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cancers with seemingly important risk from viral infections important in winter, based on correlations with increasing latitude in the United States, an index of wintertime solar ultraviolet-B dose and vitamin D, are bladder, prostate, testicular and thyroid cancer, Hodgkin's and non-Hodgkin's lymphoma, and, perhaps, gastric cancer.


55. Bernard MP, Bancos S, Sime PJ, Phipps RP: Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des; 2008;14(21):2051-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclooxygenase-2 (Cox-2), a key modulator of inflammation.
  • For example, hematological malignancies such as chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma often highly express Cox-2, which correlates with poor patient prognosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):305-15 [14970279.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):128-40 [15059134.001]
  • [Cites] Trends Immunol. 2004 Jun;25(6):328-33 [15145323.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):825-30 [15170663.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):425-33 [15621834.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2619-26 [15728468.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2504-9 [15454489.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):31-43 [15911099.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4784-91 [15731178.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):753-6 [16019514.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5504-14 [16061867.001]
  • [Cites] Cancer Biol Ther. 2005 May;4(5):571-82 [15846081.001]
  • [Cites] Cancer Immunol Immunother. 2005 Oct;54(10):981-7 [15891886.001]
  • [Cites] Eur J Haematol. 2005 Sep;75(3):212-20 [16104877.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1628-33 [16015389.001]
  • [Cites] Am J Hematol. 2005 Nov;80(3):169-73 [16247750.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1599-607 [16314473.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4330-8 [16123214.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1568-74 [16342649.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):66-76 [16399588.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1114-22 [16424048.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3321-8 [16338931.001]
  • [Cites] BMC Cancer. 2006;6:27 [16445867.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S289-92 [16507395.001]
  • [Cites] Cancer Detect Prev. 2006;30(1):99-101 [16495019.001]
  • [Cites] Mol Carcinog. 2006 Apr;45(4):250-9 [16385588.001]
  • [Cites] Am J Hematol. 2006 Apr;81(4):242-55 [16550520.001]
  • [Cites] Semin Immunol. 2006 Jun;18(3):186-92 [16737823.001]
  • [Cites] Clin Immunol. 2006 Jul;120(1):76-90 [16473553.001]
  • [Cites] Swiss Med Wkly. 2006 Jun 24;136(25-26):400-3 [16847764.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):349-50 [16848779.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(11):1581-90 [16797965.001]
  • [Cites] Immunol Invest. 2006;35(3-4):297-325 [16916756.001]
  • [Cites] Am J Epidemiol. 2006 Sep 1;164(5):497-504 [16840523.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5190-8 [16951238.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1095-101 [17016639.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2957-64 [16825494.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1863-71 [17064999.001]
  • [Cites] Leuk Res. 2000 May;24(5):385-92 [10785260.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3111-6 [10955791.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4629-37 [10969817.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):705-12 [11267984.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):94-102 [11841401.001]
  • [Cites] Trends Immunol. 2002 Mar;23(3):144-50 [11864843.001]
  • [Cites] Leukemia. 2002 May;16(5):791-8 [11986939.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):817-20 [12181051.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):38-45 [12358901.001]
  • [Cites] J Exp Med. 2003 Jan 20;197(2):221-32 [12538661.001]
  • [Cites] Trends Pharmacol Sci. 2003 Feb;24(2):96-102 [12559775.001]
  • [Cites] Am J Epidemiol. 2003 Mar 15;157(6):510-6 [12631540.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E14 [17134116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):31-8 [17049184.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):547-51 [16962170.001]
  • [Cites] Inflammopharmacology. 2007 Feb;15(1):1-4 [17323186.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):217-23 [17306521.001]
  • [Cites] Rheumatology (Oxford). 2007 Apr;46(4):690-4 [17148471.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jan;1095:99-112 [17404023.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):269-75 [17224647.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):95-105 [17315190.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):327-34 [17537668.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):247-56 [18231910.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] BMC Cancer. 2008;8:4 [18190720.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11 [15179620.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4309-18 [15205346.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1862-6 [15222024.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1395-9 [15359639.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1495-6 [15359658.001]
  • [Cites] Cancer Lett. 2004 Nov 8;215(1):1-20 [15374627.001]
  • [Cites] Clin Exp Immunol. 1983 Jan;51(1):61-8 [6572580.001]
  • [Cites] J Immunol. 1983 Oct;131(4):1734-41 [6604751.001]
  • [Cites] Acta Haematol. 1985;74(3):132-6 [3938156.001]
  • [Cites] J Immunol. 1986 Jun 15;136(12):4652-8 [2940298.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Surg Today. 1995;25(11):954-8 [8640020.001]
  • [Cites] Blood. 1997 Jul 1;90(1):260-9 [9207461.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):455-9 [10226582.001]
  • [Cites] Stem Cells Dev. 2004 Oct;13(5):484-95 [15588506.001]
  • [Cites] Int J Biol Sci. 2007;3(5):328-34 [17589567.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):878-83 [17450522.001]
  • [Cites] Subcell Biochem. 2007;42:93-126 [17612047.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):705-10 [17546626.001]
  • [Cites] Clin Immunol. 2007 Nov;125(2):138-48 [17728187.001]
  • [Cites] Clin Exp Med. 2007 Sep;7(3):83-97 [17972050.001]
  • [Cites] Am J Pathol. 2007 Nov;171(5):1538-48 [17823287.001]
  • [Cites] Mol Carcinog. 2007 Dec;46(12):971-80 [17477358.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2512-8 [17713545.001]
  • [Cites] Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15 [18056932.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Cancer Immunol Immunother. 2008 Mar;57(3):347-58 [17668203.001]
  • [Cites] Ann Hematol. 2008 Feb;87(2):121-9 [17999062.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):60-7 [18181047.001]
  • [Cites] Mol Ther. 2008 Feb;16(2):269-79 [18071334.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1418-23 [10581086.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):605-10 [10583266.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11397-403 [10753955.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):469-79 [12734098.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):534-7 [12814999.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):784-8 [12866040.001]
  • [Cites] Leuk Res. 2004 Feb;28(2):179-90 [14654083.001]
  • (PMID = 18691115.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL088325; United States / NIDCR NIH HHS / DE / DE007202-16; United States / NIDCR NIH HHS / DE / T32-DE007202; United States / NHLBI NIH HHS / HL / HL075432; United States / NEI NIH HHS / EY / EY017123; United States / NIDCR NIH HHS / DE / DE011390; United States / NHLBI NIH HHS / HL / R01 HL088325; United States / NIAID NIH HHS / AI / AI071064-02; United States / NIDCR NIH HHS / DE / R01 DE011390; United States / NIAID NIH HHS / AI / AI071064; United States / NIAID NIH HHS / AI / R21 AI071064-02; United States / NHLBI NIH HHS / HL / HL075432-03; United States / NIAID NIH HHS / AI / R21 AI071064; United States / NHLBI NIH HHS / HL / R01 HL075432; United States / NHLBI NIH HHS / HL / R01 HL088325-02; United States / NIDCR NIH HHS / DE / T32 DE007202; United States / NHLBI NIH HHS / HL / R01 HL075432-03; United States / NIDCR NIH HHS / DE / T32 DE007202-16; United States / NHLBI NIH HHS / HL / HL088325-02; United States / NHLBI NIH HHS / HL / T32 HL066988
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 111
  • [Other-IDs] NLM/ NIHMS137022; NLM/ PMC2745246
  •  go-up   go-down


56. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D: Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer; 2005 Apr 25;92(8):1352-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
  • There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma.
  • We evaluated the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma / drug therapy. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1994;5 Suppl 2:91-5 [7515652.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):543-9 [8573532.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9 [7481849.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Bone Marrow Transplant. 1997 Jul;20(1):21-6 [9232251.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):525-9 [9261520.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3264-9 [9779700.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3562-8 [9808548.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):351-4 [10355582.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):981-90 [10362105.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):943-7 [10509156.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3776-85 [10577849.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3786-92 [10577850.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Ann Oncol. 2000 May;11(5):595-7 [10907954.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Biochem Pharmacol. 2001 Jun 1;61(11):1401-8 [11331076.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):786-92 [11843810.001]
  • [Cites] N Engl J Med. 2002 May 2;346(18):1417-8 [11986425.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):311-5 [12201493.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1):17-21 [12504621.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):970-7 [12648066.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):621-30 [12537665.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1963-70 [12799644.001]
  • [Cites] Rev Mal Respir. 2003 Apr;20(2 Pt 1):201-6 [12844017.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):978-82 [12942565.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):363-8 [15140550.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2424-9 [15136597.001]
  • [Cites] Oncology. 2004;66(3):197-200 [15218310.001]
  • [Cites] Clin Lymphoma. 2004 Jun;5(1):45-9 [15245607.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):406-13 [1740680.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • (PMID = 15812553.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC2361993
  •  go-up   go-down


57. Blair A, Freeman LB: Epidemiologic studies in agricultural populations: observations and future directions. J Agromedicine; 2009;14(2):125-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meta-analyses of mortality surveys of farmers find excesses of several cancers, including connective tissue, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma and cancers of the skin, stomach, and brain, and deficits for total mortality, heart disease, total cancer, and cancers of the esophagus, colon, lung, and bladder.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Work Environ Health. 1999 Oct;25(5):436-41 [10569464.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2009 Sep;19(6):544-54 [19052531.001]
  • [Cites] Am J Ind Med. 2001 Nov;40(5):604-11 [11675631.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):634-42 [12937183.001]
  • [Cites] Scand J Work Environ Health. 1992 Aug;18(4):209-15 [1411362.001]
  • [Cites] Int Arch Occup Environ Health. 1993;65(3):163-9 [8282414.001]
  • [Cites] Am J Ind Med. 1996 May;29(5):501-6 [8732923.001]
  • [Cites] Am J Ind Med. 1997 Nov;32(5):510-6 [9327075.001]
  • [Cites] Ann Epidemiol. 1998 Jan;8(1):64-74 [9465996.001]
  • [Cites] Am J Ind Med. 1998 Sep;34(3):252-60 [9698994.001]
  • [Cites] Scand J Work Environ Health. 1998 Aug;24(4):255-61 [9754856.001]
  • [Cites] Occup Environ Med. 1999 Jan;56(1):14-21 [10341741.001]
  • [Cites] Occup Environ Med. 1999 Aug;56(8):548-52 [10492653.001]
  • [Cites] Ann Epidemiol. 2005 Apr;15(4):279-85 [15780775.001]
  • [Cites] Am J Epidemiol. 2005 Jun 1;161(11):1037-46 [15901624.001]
  • [Cites] Cancer Causes Control. 2005 May;16(4):389-97 [15953981.001]
  • [Cites] Scand J Work Environ Health. 2005;31 Suppl 1:9-17; discussion 5-7 [16190144.001]
  • [Cites] Scand J Work Environ Health. 2005;31 Suppl 1:39-45; discussion 5-7 [16190148.001]
  • [Cites] Ann Occup Hyg. 2007 Jan;51(1):53-65 [16984946.001]
  • [Cites] Cancer Causes Control. 2007 Jun;18(5):457-78 [17443416.001]
  • [Cites] Am J Ind Med. 2001 Nov;40(5):596-603 [11675630.001]
  • (PMID = 19437268.001).
  • [ISSN] 1545-0813
  • [Journal-full-title] Journal of agromedicine
  • [ISO-abbreviation] J Agromedicine
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010119-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrochemicals
  • [Number-of-references] 22
  • [Other-IDs] NLM/ NIHMS90319; NLM/ PMC2682692
  •  go-up   go-down


58. Hemminki K, Eng C, Chen B: Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab; 2005 Oct;90(10):5747-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hurthle cell tumors were associated with Hodgkin's and non-Hodgkin's lymphoma, but the numbers of cases were small.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030170.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Okines A, Thomson CS, Radstone CR, Horsman JM, Hancock BW: Second primary malignancies after treatment for malignant lymphoma. Br J Cancer; 2005 Aug 22;93(4):418-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary malignancies after treatment for malignant lymphoma.
  • To determine the incidence and possible causes of second primary malignancies after treatment for Hodgkin's and Non-Hodgkin's lymphoma (HL and NHL).
  • A cohort of 3764 consecutive patients diagnosed with HL or NHL between January 1970 and July 2001 was identified using the Sheffield Lymphoma Group database.
  • [MeSH-major] Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):498-509 [10653865.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):732-41 [7563150.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):318-22 [11886011.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3484-94 [12177110.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3388-90 [12900526.001]
  • [Cites] Lancet. 1975 Apr 26;1(7913):947-9 [48122.001]
  • [Cites] J Natl Cancer Inst. 1995 Oct 18;87(20):1530-7 [7563187.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Br J Cancer. 1997;75(1):116-23 [9000608.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1203-10 [9070499.001]
  • [Cites] Blood. 1957 Sep;12(9):788-803 [13459926.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] N Engl J Med. 1982 Oct 14;307(16):965-71 [7110299.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1891-8 [6572558.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):830-7 [3711960.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):252-4 [3334958.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Br J Cancer. 1988 Oct;58(4):512-7 [3207608.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):80-8 [2354413.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):432-7 [1999712.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):2002-9 [2004317.001]
  • [Cites] BMJ. 1992 May 2;304(6835):1137-43 [1392790.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):25-31 [8416252.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):255-61 [8426202.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):925-30 [8487056.001]
  • [Cites] J Natl Cancer Inst. 1993 Dec 1;85(23):1932-7 [8230284.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):312-25 [8113838.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1063-73 [8164031.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3437-40 [8204870.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):947-55 [10694543.001]
  • (PMID = 16106249.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361580
  •  go-up   go-down


60. Wang J, Sun NC, Chen YY, Weiss LM: T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases.
  • T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), a proliferating peripheral B-cell neoplasm, is a morphologic variant of diffuse large B-cell lymphoma (DLBCL), which may be confused with Hodgkin's lymphoma, non-Hodgkin's lymphoma, and reactive lymphadenopathies.
  • Lack of Bcl-2 gene rearrangements seems to argue against a possible progression from preexisting follicular lymphoma.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894921.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


61. Horneff G: [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis]. Z Rheumatol; 2010 Aug;69(6):516-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Reports on malignancies observed in children exposed to TNF-inhibitors have raised questions about a potentially increased risk for lymphoma in particular.
  • RESULTS: Between 2001 and 2009 five cases of malignancy were documented in the German JIA Etanercept in Children Registry covering 1200 patients, including one case each of non-Hodgkin's lymphoma, Hodgkin's lymphoma, thyroid cancer, yolk sac cancer, and cervical dysplasia.
  • [MeSH-minor] Adalimumab. Adolescent. Adult. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Child. Cross-Sectional Studies. Drug Therapy, Combination. Etanercept. Germany. Humans. Immunoglobulin G / adverse effects. Immunoglobulin G / therapeutic use. Leukemia / chemically induced. Leukemia / epidemiology. Lymphoma / chemically induced. Lymphoma / epidemiology. Receptors, Tumor Necrosis Factor / therapeutic use. Registries. Risk Factors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • Hazardous Substances Data Bank. Etanercept .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20532787.001).
  • [ISSN] 1435-1250
  • [Journal-full-title] Zeitschrift für Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Biological Products; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


62. Yang BB, Kido A, Shibata A: Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy; 2007 Oct;27(10):1387-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: A total of 370 patients with non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or breast cancer.
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / drug therapy. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Dose-Response Relationship, Drug. Filgrastim. Humans. Leukocyte Count. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / drug therapy. Randomized Controlled Trials as Topic. Recombinant Proteins. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17896894.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


63. Frobisher C, Lancashire ER, Reulen RC, Winter DL, Stevens MC, Hawkins MM, British Childhood Cancer Survivor Study: Extent of alcohol consumption among adult survivors of childhood cancer: the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1174-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, survivors of Hodgkin's lymphoma, non-Hodgkin's lymphoma, Wilms' tumor, bone sarcoma, and soft tissue sarcoma had adverse drinking behaviors at levels expected from the general population.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • (PMID = 20447915.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Easton D; Hawkins M; Jenkinson H; Jenney M; Lancashire E; Pritchard-Jones K; Stevens M; Stiller C; Sugden E; Toogood A; Wallace H
  •  go-up   go-down


64. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, SPAT Group: Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect; 2010 Dec;138(12):1804-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More modestly increased rates of IPD were found in those with chronic lymphocytic leukaemia, acute myeloid leukaemia, acute lymphoblastic leukaemia, and Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429967.001).
  • [ISSN] 1469-4409
  • [Journal-full-title] Epidemiology and infection
  • [ISO-abbreviation] Epidemiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Grant WB: How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer?: An examination using Hill's criteria for causality. Dermatoendocrinol; 2009 Jan;1(1):17-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results for breast and colorectal cancer satisfy the criteria best, but there is also good evidence that other cancers do as well, including bladder, esophageal, gallbladder, gastric, ovarian, rectal, renal and uterine corpus cancer, as well as Hodgkin's and non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5596-602 [18936471.001]
  • [Cites] Urology. 2008 Mar;71(3):531-5 [18342203.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1690-4 [18092326.001]
  • [Cites] Carcinogenesis. 2008 Jan;29(1):93-9 [17974532.001]
  • [Cites] Curr Med Res Opin. 2008 Jan;24(1):139-49 [18034918.001]
  • [Cites] Epidemiol Infect. 2008 Jan;136(1):1-9 [17553179.001]
  • [Cites] J Epidemiol Community Health. 2008 Jan;62(1):69-74 [18079336.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):12-5 [17967529.001]
  • [Cites] Ann Epidemiol. 2007 Dec;17(12):956-63 [18022535.001]
  • [Cites] Prev Med. 2007 Nov;45(5):327-31 [17395256.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1889-93 [17855710.001]
  • [Cites] Int J Health Geogr. 2007;6:34 [17651508.001]
  • [Cites] Eur J Dermatol. 2007 Sep-Oct;17(5):428-34 [17673388.001]
  • [Cites] Acta Pharmacol Sin. 2007 Sep;28(9):1373-82 [17723171.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):236-42 [17696738.001]
  • [Cites] Prostate. 2007 Sep 1;67(12):1362-70 [17624920.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1701-12 [17540555.001]
  • [Cites] Dis Markers. 2007;23(4):247-59 [17627060.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):123-8 [17551495.001]
  • [Cites] Am J Clin Nutr. 2007 Jun;85(6):1586-91 [17556697.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1283-6 [17548698.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1554-9 [17453003.001]
  • [Cites] Ann Neurol. 2007 Apr;61(4):288-99 [17444504.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;102(3):323-8 [17028983.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11 [17368188.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):668-74 [17208438.001]
  • [Cites] Am J Clin Nutr. 2007 Mar;85(3):860-8 [17344510.001]
  • [Cites] Lung Cancer. 2007 Mar;55(3):263-70 [17207891.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):479-85 [17290055.001]
  • [Cites] Am J Prev Med. 2007 Mar;32(3):210-6 [17296473.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1123-8 [17149699.001]
  • [Cites] Am J Prev Med. 2006 Dec;31(6):512-4 [17169713.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2467-72 [17132768.001]
  • [Cites] BMC Cancer. 2006;6:264 [17096841.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10213-9 [17047087.001]
  • [Cites] Epidemiol Infect. 2006 Dec;134(6):1129-40 [16959053.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2705-9 [16981191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1688-95 [16985031.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1091-101 [16933060.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1530-6 [16671100.001]
  • [Cites] ChemMedChem. 2006 Aug;1(8):783-802 [16902931.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2687-99 [16886679.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4A):2605-14 [16886670.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] J Natl Med Assoc. 2006 Mar;98(3):357-64 [16573299.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):669-83 [16481635.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2303-9 [16214909.001]
  • [Cites] J Nutr. 2005 Oct;135(10):2350-4 [16177194.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):571-4 [16136030.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3274-8 [18990771.001]
  • [Cites] Am J Pathol. 2008 Nov;173(5):1589-90 [18948436.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2398-407 [18816636.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41 [18525006.001]
  • [Cites] Anticancer Res. 2008 May-Jun;28(3B):1955-63 [18630488.001]
  • [Cites] BMJ. 2008 Jun 14;336(7657):1318-9 [18556276.001]
  • [Cites] Eur J Surg Oncol. 2008 Jul;34(7):765-70 [18160246.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2984-91 [18565885.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):796-804 [18505967.001]
  • [Cites] Am J Pathol. 2008 Jun;172(6):1717-28 [18483213.001]
  • [Cites] Cancer Causes Control. 2008 Jun;19(5):527-35 [18219582.001]
  • [Cites] Diabetes Care. 2008 Apr;31(4):701-7 [18235052.001]
  • [Cites] Adv Exp Med Biol. 2008;624:104-16 [18348451.001]
  • [Cites] Adv Exp Med Biol. 2008;624:43-54 [18348446.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):195-9 [15687362.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):429-40 [15539405.001]
  • [Cites] Health Phys. 2004 Nov;87(5):532-8 [15551791.001]
  • [Cites] Proc R Soc Med. 1965 May;58:295-300 [14283879.001]
  • [Cites] Photochem Photobiol. 1999 Aug;70(2):243-7 [10461463.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):425-32 [9794175.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):323-31 [9031113.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 6;88(21):1560-70 [8901854.001]
  • [Cites] Sci Am. 1996 Jul;275(1):52-3, 56-9 [8658110.001]
  • [Cites] BMJ. 1996 May 4;312(7039):1128-31 [8620128.001]
  • [Cites] Ann Med. 1995 Oct;27(5):565-8 [8541033.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 5;86(1):33-8 [8271280.001]
  • [Cites] Int J Epidemiol. 1994 Dec;23(6):1133-6 [7721513.001]
  • [Cites] Lancet. 1985 Feb 9;1(8424):307-9 [2857364.001]
  • [Cites] Jpn J Clin Oncol. 1985 Jun;15(2):403-13 [4021121.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Rev Infect Dis. 1982 Nov-Dec;4(6):1270-4 [6818657.001]
  • [Cites] Lancet. 1981 Nov 28;2(8257):1185-90 [6118627.001]
  • [Cites] Lancet. 1982 Jan 9;1(8263):74-6 [6119494.001]
  • [Cites] Int J Epidemiol. 1980 Sep;9(3):227-31 [7440046.001]
  • [Cites] Int J Cancer. 1975 Apr 15;15(4):617-31 [1140864.001]
  • [Cites] Nutr Cancer. 2004;48(2):115-23 [15231446.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1042-51 [15184262.001]
  • [Cites] Cancer Causes Control. 2004 Mar;15(2):149-58 [15017127.001]
  • [Cites] Eur Urol. 2004 Mar;45(3):271-9 [15036670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):59-64 [14744734.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):694-704 [14710348.001]
  • [Cites] Recent Results Cancer Res. 2003;164:99-110 [12908448.001]
  • [Cites] Recent Results Cancer Res. 2003;164:371-7 [12899536.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] Ann Epidemiol. 2003 Jul;13(6):395-404 [12875796.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):363-71 [12520538.001]
  • [Cites] Br J Dermatol. 2002 Aug;147(2):197-213 [12174089.001]
  • [Cites] Occup Environ Med. 2002 Apr;59(4):257-62 [11934953.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1867-75 [11920550.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):272-81 [11815987.001]
  • [Cites] Lung Cancer. 2002 Jan;35(1):43-51 [11750712.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):837-46 [11312434.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Aug;14(4):797-807, viii [10949774.001]
  • [Cites] Health Place. 1998 Dec;4(4):355-64 [10670982.001]
  • [Cites] Curr Pharm Des. 2000 May;6(7):717-32 [10828303.001]
  • [Cites] Eur J Clin Nutr. 1999 Dec;53(12):920-6 [10602348.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Feb;4(2):80-90 [18212810.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2 [18202430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):668-73 [18180454.001]
  • [Cites] Ann Epidemiol. 1993 Jan;3(1):103-10 [8287144.001]
  • [Cites] Prev Med. 1990 Nov;19(6):614-22 [2263572.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1307-11 [2241107.001]
  • (PMID = 20046584.001).
  • [ISSN] 1938-1980
  • [Journal-full-title] Dermato-endocrinology
  • [ISO-abbreviation] Dermatoendocrinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2715209
  • [Keywords] NOTNLM ; association / breast cancer / colon cancer / dose-response / ecologic / mechanisms / observational / supplements / viral infections
  •  go-up   go-down


66. Krishnan A, Levine AM: Malignancies in women with HIV infection. Womens Health (Lond); 2008 Jul;4(4):357-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of other types of malignancies, such as Hodgkin's and non-Hodgkin's lymphoma, is also increased in HIV-infected individuals.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active / statistics & numerical data. Comorbidity. Disease-Free Survival. Female. Hodgkin Disease / epidemiology. Humans. Lymphoma, Non-Hodgkin / epidemiology. Risk Factors


67. Papadopoulos KP, Noguera-Irizarry W, Wiebe L, Hesdorffer CS, Garvin J, Nichols GL, Vahdat LH, Lo KM, Skerrett D, Bernstein D, Sharpe E, Savage DG: Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma. Bone Marrow Transplant; 2005 Sep;36(6):491-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.
  • In an effort to improve the outcome of poor-risk lymphoma patients, we evaluated a novel regimen of tandem high-dose chemotherapy (THDC) with autologous stem cell transplantation.
  • A total of 41 patients (median age 40 years, range 15-68 years) with poor-risk non-Hodgkin's lymphoma and Hodgkin's disease were enrolled.
  • This THDC regimen is feasible but with notable toxicity in heavily pretreated patients; its role in the current treatment of high-risk lymphoma remains to be determined.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044139.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


68. Mondin V, Ferlito A, Devaney KO, Woolgar JA, Rinaldo A: A survey of metastatic central nervous system tumors to cervical lymph nodes. Eur Arch Otorhinolaryngol; 2010 Nov;267(11):1657-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Less often, both adults and children may present with cervical masses caused by either non-Hodgkin's lymphoma or Hodgkin's disease.
  • Cervical node metastases may arise from glial tumors (including glioblastoma multiforme, in both adult and pediatric patients) and non-glial tumors (such as medulloblastoma in pediatric patients).

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694730.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


69. Aguayo P, Ho B, Fraser JD, Gamis A, St Peter SD, Snyder CL: Bowel obstruction after treatment of intra-abdominal tumors. Eur J Pediatr Surg; 2010 Jul;20(4):234-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective data analysis of all patients diagnosed with intra-abdominal Wilms' tumor, rhabdomyosarcoma, neuroblastoma, and Hodgkin's and non-Hodgkin's lymphoma in a single institution from 1997 to 2007 was conducted.
  • Tumor distribution was as follows: Wilms' tumor: 56 (19%); non-Hodgkin's lymphoma: 71 (24%); Hodgkin's lymphoma: 64 (22%); rhabdomyosarcoma: 32 (11%); and neuroblastoma: 68 (24%).
  • Wilms' tumor, rhabdomyosarcoma and Burkitt's lymphoma appear to be associated with the highest risk of bowel obstruction.

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496318.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


70. Mohammed A, Aliyu HO: Childhood cancers in a referral hospital in northern Nigeria. Indian J Med Paediatr Oncol; 2009 Jul;30(3):95-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Burkitt's lymphoma accounted for 27.01% of the cases followed by retinoblastoma (17.02%), non-Hodgkin's non-Burkitt's Lymphoma (9.42%), and Rhabdomyosarcoma (9.42%).
  • Others were Nephroblastoma (8.81%), Hodgkin's lymphoma (6.69%), Neuroblastoma (3.34%), Colorectal carcinoma (2.43%), Osteosarcoma (2.13%), and Unspecified lymphomas (1.82%).
  • Burkitt's lymphoma was most prevalent in the 5-9 and 10-15 year age groups, retinoblastoma in the 0-4 year age group, and Non-Hodgkin's lymphoma, Hodgkin's lymphoma, and unspecified carcinomas were more prevalent in the 10-15 year age group.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838544.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2930295
  • [Keywords] NOTNLM ; Childhood cancers / Nigeria / lymphoma
  •  go-up   go-down


71. Olu-Eddo AN, Ohanaka CE: Peripheral lymphadenopathy in Nigerian adults. J Pak Med Assoc; 2006 Sep;56(9):405-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non Hodgkin's lymphoma and Hodgkin's lymphoma (HL) constituted 69 (16.2%) and 43 (10.1%) cases respectively.
  • Non specific lymphadenitis and onchocerciasis comprised 81 (19.0%) and 4 (0.9%) cases respectively.

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091753.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


72. Lin P, Chu J, Kneebone A, Moylan E, Jalaludin B, Pocock N, Kiat H, Rosenfeld D: Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma. Intern Med J; 2005 Feb;35(2):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma.
  • BACKGROUND: The present study compared the performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) using a coincidence dual-head gamma camera (FDG Co-PET) with 67gallium scinti graphy (GS) in pretreatment staging of lymphoma.
  • METHODS: A total of 46 patients underwent FDG Co-PET, computed tomography (CT) scanning and GS for pretreatment staging of lymphoma (40 newly diagnosed and recurrence) between November 1997 and December 1999.
  • RESULTS: Histological subgroups comprised low grade (8 patients), intermediate grade (25) high-grade (3) non-Hodgkin's lymphoma and Hodgkin's disease (10).
  • CONCLUSION: FDG Co-PET shows potential for providing an accurate means for pretreatment staging of lymphoma and can detect extra sites of disease activity compared to GS.
  • [MeSH-major] Fluorodeoxyglucose F18. Gallium Radioisotopes. Lymphoma / radionuclide imaging. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15705137.001).
  • [ISSN] 1444-0903
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


73. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum; 2010 Aug;62(8):2517-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Half of the malignancies reported were lymphomas and included both Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2010 Aug;62(8):2183-4 [20506203.001]
  • (PMID = 20506368.001).
  • [ISSN] 1529-0131
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


74. Monnereau A, Orsi L, Troussard X, Berthou C, Fenaux P, Soubeyran P, Marit G, Huguet F, Milpied N, Leporrier M, Hemon D, Clavel J: Cigarette smoking, alcohol drinking, and risk of lymphoid neoplasms: results of a French case-control study. Cancer Causes Control; 2008 Dec;19(10):1147-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases were newly diagnosed with non-Hodgkin's or Hodgkin's lymphoma, multiple myeloma, or lymphoproliferative syndrome (LPS).
  • However, average tobacco consumption tended to be inversely related to non-Hodgkin's lymphoma (NHL), LPS, and the hairy cell leukemia (HCL) subtype, with a significant negative trend for the latter (OR of 0.4, 0.2, 0.1 for consumptions of <or=10, 11-20, >20 cig/day).
  • An inverse association between 'ever drinking' and Hodgkin's lymphoma (HL: OR = 0.5 [0.3-0.8]) and NHL (OR = 0.7 [0.5-1.0]) was evidenced and restricted to the diffuse large B-cell lymphoma subtype, with significant negative trends.
  • The negative relationship between alcohol consumption and Hodgkin's and NHL, also previously reported, needs further investigations.
  • [MeSH-major] Alcohol Drinking / adverse effects. Hodgkin Disease / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Multiple Myeloma / epidemiology. Smoking / adverse effects


75. Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N: Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis; 2006 Sep;65(9):1184-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study.
  • BACKGROUND: Several inflammatory conditions are associated with an increased risk of lymphoma.
  • There are few studies on whether ankylosing spondylitis increases the risk of lymphoma.
  • Besides inflammation-lymphoma aetiology, information on risk of lymphoma in ankylosing spondylitis is particularly important as a benchmark in the evaluation of, for example, tumour necrosis factor inhibitors.
  • METHODS: The association between ankylosing spondylitis and malignant lymphomas overall, and separately for non-Hodgkin's lymphoma, Hodgkin's lymphoma and chronic lymphocytic leukaemia, was assessed in a nationwide, population-based case-control study of 50 615 cases of lymphoma and 92 928 matched controls by using prospectively recorded data on lymphomas from the Swedish Cancer Register (1964-2000) and data on pre-lymphoma hospitalisations for ankylosing spondylitis from the Swedish Inpatient Register (1964-2000).
  • The odds ratios (ORs) associated with pre-lymphoma hospitalisation for ankylosing spondylitis were calculated using conditional logistic regression.
  • RESULTS: 23 (0.05%) patients with lymphoma and 41 (0.05%) controls had a pre-lymphoma hospitalisation listing ankylosing spondylitis, relative risk = 1.0 (95% confidence interval (CI) 0.6 to 1.7).
  • The number of discharges and the mean latency between ankylosing spondylitis and lymphoma were similar in patients and controls.
  • CONCLUSIONS: On average and in the absence of tumour necrosis factor inhibitors, patients hospitalised with ankylosing spondylitis do not appreciably show an increased risk of lymphoma.
  • [MeSH-major] Lymphoma / etiology. Spondylitis, Ankylosing / complications
  • [MeSH-minor] Adult. Aged. Epidemiologic Methods. Female. Hospitalization / statistics & numerical data. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Sweden / epidemiology


76. Martin S, Ulrich C, Munsell M, Taylor S, Lange G, Bleyer A: Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist; 2007 Jul;12(7):816-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data on 270 patients with the six most common cancer types in this cohort (leukemia, Hodgkin's and non-Hodgkin's lymphoma, sarcoma, brain tumors, thyroid cancer) were retrospectively collected in 2004.

  • MedlinePlus Health Information. consumer health - Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673613.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Mols F, Thong MS, Vreugdenhil G, van de Poll-Franse LV: Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology; 2009 Dec;18(12):1252-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All 1893 long-term survivors of prostate cancer, endometrial cancer, non-Hodgkin's lymphoma, and Hodgkin's lymphoma diagnosed between 1989 and 1998 in the area of the Comprehensive Cancer Centre South, The Netherlands were included in a population-based cross-sectional survey.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Comorbidity. Cross-Sectional Studies. Disease Progression. Educational Status. Endometrial Neoplasms / psychology. Endometrial Neoplasms / rehabilitation. Female. Health Surveys. Hodgkin Disease / psychology. Hodgkin Disease / rehabilitation. Humans. Lymphoma, Non-Hodgkin / psychology. Lymphoma, Non-Hodgkin / rehabilitation. Male. Middle Aged. Netherlands. Prostatic Neoplasms / psychology. Prostatic Neoplasms / rehabilitation. Quality of Life / psychology. Retirement. Risk Factors. Work Schedule Tolerance

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156675.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


78. Krawczuk-Rybak M, Solarz E, Gadomski J, Matysiak M, Wołczyński S: [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):623-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood].
  • AIM: To investigate testicular function (spermato- and steroidogenesis) in adolescents and young men cured of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Combined Modality Therapy / adverse effects. Gonadotropins, Pituitary / blood. Hodgkin Disease / therapy. Infertility, Male / etiology. Lymphoma, Non-Hodgkin / therapy. Spermatogenesis / drug effects. Spermatogenesis / radiation effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317893.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Gonadotropins, Pituitary; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


79. Divgi C: Imaging: staging and evaluation of lymphoma using nuclear medicine. Semin Oncol; 2005 Feb;32(1 Suppl 1):S11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging: staging and evaluation of lymphoma using nuclear medicine.
  • The management of lymphoma is dependent on accurate staging of the disease and evaluation of histology and other risk factors.
  • Many studies have indicated that FDG-PET is as good as or better than 67 Ga-SPECT for the detection of lymphoma.
  • At present, FDG-PET scanning is not routinely available in all institutions; however, a role can be indicated for FDG-PET in several areas of lymphoma management, including initial staging, predicting response to therapy (during and following chemotherapy), and identification of residual tumor.
  • This article examines the role of the different imaging techniques available and the use of these techniques in the staging and evaluation of patients with Hodgkin's and non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / radionuclide imaging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786021.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


80. Grant WB, Boucher BJ: Current impediments to acceptance of the ultraviolet-B-vitamin D-cancer hypothesis. Anticancer Res; 2009 Sep;29(9):3597-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are about 14 types of cancer for which it seems to apply: bladder, breast, colon, endometrial, esophageal, gallbladder, gastric, ovarian, pancreatic, rectal, renal and vulvar cancer and both Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667154.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 98
  •  go-up   go-down


81. Leone G, Pagano L, Ben-Yehuda D, Voso MT: Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica; 2007 Oct;92(10):1389-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.
  • Patients with Hodgkin's and non-Hodgkin's lymphoma are at highest risk when total body irradiation followed by autologous stem cell transplantation is used as rescue or consolidation therapy.
  • In non-hematologic malignancies, treatment for breast cancer and germ-cell tumors has been associated with a 1-5% lifetime risk of both lymphoid as well as myeloid leukemia.


82. Adesuwa Olu-Eddo N, Egbagbe EE: Peripheral lymphadenopathy in Nigerian children. Niger J Clin Pract; 2006 Dec;9(2):134-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-specific reactive changes, non Hodgkin's lymphoma, Hodgkin's lymphoma and metastatic carcinoma were seen in 32 (25.4%), 22 (17.4%), 7 (5.6%), and 2 (1.6%) cases respectively.
  • The triad of symptoms including fever, fatigue and weight loss, were recurrent in tuberculous and lymphoma patients.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymph Nodes / pathology. Lymphatic Diseases / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Tuberculosis, Lymph Node / diagnosis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319345.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


83. Wong SF, Chan HO: Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Pharmacotherapy; 2005 Mar;25(3):372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: Fifty-six patients aged 18 years or older with breast cancer, lung cancer, melanoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma who developed neutropenia within 4 weeks after treatment with myelosuppressive chemotherapy and who had been given five or more doses of CSF as primary or secondary prophylaxis from January 1995-March 2002.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pharmacotherapy. 2006 Mar;26(3):443-4; discussion 444 [16503728.001]
  • (PMID = 15843284.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


84. Grant WB, Garland CF, Gorham ED: An estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of oral vitamin D per day. Recent Results Cancer Res; 2007;174:225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solar ultraviolet B (UVB) irradiance and/or vitamin D have been found inversely correlated with incidence, mortality, and/or survival rates for breast, colorectal, ovarian, and prostate cancer and Hodgkin's and non-Hodgkin's lymphoma.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302200.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 86
  •  go-up   go-down


85. Zonenberg A, Zarzycki W, Leoniak M: [The effect of Chernobyl accident on the development of malignant diseases--situation after 20 years]. Endokrynol Pol; 2006 May-Jun;57(3):244-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data obtained from the regions near Chernobyl showed no increased risk of other types of malignancy (leukaemia, Hodgkin's and non Hodgkin's lymphoma) in 1986-1996.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832789.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Radioactive Fallout
  • [Number-of-references] 70
  •  go-up   go-down


86. Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S: Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion; 2007 Dec;47(12):2207-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This retrospective study included patients with diagnoses of acute myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, and solid tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / analysis. Child. Child, Preschool. Combined Modality Therapy. Female. Granulocyte Colony-Stimulating Factor / pharmacology. Hodgkin Disease / metabolism. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / metabolism. Multiple Myeloma / therapy. Prognosis. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714420.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / P30 CA33572
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


87. Chen KN, Xu SF, Gu ZD, Zhang WM, Pan H, Su WZ, Li JY, Xu GW: Surgical treatment of complex malignant anterior mediastinal tumors invading the superior vena cava. World J Surg; 2006 Feb;30(2):162-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymic carcinoma, teratoma, embryonal carcinoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and mixed teratoma with thymoma were diagnosed in 1 patient each.
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Angiography. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / mortality. Preoperative Care. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Thymectomy / methods. Thymoma / drug therapy. Thymoma / mortality. Thymoma / pathology. Thymoma / surgery. Thymus Neoplasms / drug therapy. Thymus Neoplasms / mortality. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425072.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Marchesoni D, Driul L, Fruscalzo A, Santuz M, Calcagno A, Ianni A, Geromin A, Fanin R: [Premature ovarian failure in patients affected by oncohematological disease]. Minerva Ginecol; 2005 Oct;57(5):545-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From April 1996 to May 2002 a total of 49 fertile women affected by oncohematological diseases (Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute leukemia) and treated with chemotherapy were evaluated.

  • Genetic Alliance. consumer health - premature ovarian failure.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205599.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptives, Oral; 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


89. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ; 2009 Dec 08;339:b4606
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: 14,358 five year survivors of cancer diagnosed under the age of 21 with leukaemia, brain cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, kidney cancer, neuroblastoma, soft tissue sarcoma, or bone cancer between 1970 and 1986.
  • Cardiac radiation exposure of 1500 centigray or more increased the relative hazard of congestive heart failure, myocardial infarction, pericardial disease, and valvular abnormalities by twofold to sixfold compared to non-irradiated survivors.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Saf. 2000 Apr;22(4):263-302 [10789823.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):31-7 [3581032.001]
  • [Cites] Stat Med. 1990 May;9(5):505-14 [2190287.001]
  • [Cites] Am J Cardiol. 1975 Feb;35(2):216-20 [1119380.001]
  • [Cites] Chest. 1991 Mar;99(3):538-45 [1995208.001]
  • [Cites] Am J Hematol. 1991 Mar;36(3):217-8 [1705095.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] JAMA. 1991 Sep 25;266(12):1672-7 [1886191.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):182-8 [8004574.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):328-31 [8636739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Nov 1;36(4):881-9 [8960517.001]
  • [Cites] Am J Med Sci. 1997 Dec;314(6):399-400 [9413345.001]
  • [Cites] Radiother Oncol. 1999 Apr;51(1):35-42 [10386715.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2629-36 [15837978.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jun 15;44(7):600-6 [15856486.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 May;17(3):153-9 [15900998.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):173-85 [15896910.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):324-32 [15714447.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7685-96 [16234530.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] J Clin Epidemiol. 2006 Aug;59(8):862-7 [16828682.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3191-8 [16987655.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1878-86 [17119114.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3635-43 [17704413.001]
  • [Cites] Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120 [18512336.001]
  • [Cites] Curr Treat Options Oncol. 2008 Feb;9(1):51-66 [18363110.001]
  • [Cites] BMC Cancer. 2008;8:141 [18492236.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4401-9 [18802152.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2319-27 [19364957.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(11):1191-6 [10849532.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):429-47 [11139373.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] Arch Intern Med. 2001 Jan 22;161(2):277-84 [11176744.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1926-34 [11283124.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] JAMA. 2002 Apr 10;287(14):1832-9 [11939869.001]
  • [Cites] Med Pediatr Oncol. 2002 Aug;39(2):86-92 [12116055.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] J Am Coll Cardiol. 2003 Aug 20;42(4):743-9 [12932613.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Am J Epidemiol. 2003 Dec 1;158(11):1108-13 [14630607.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):769-73 [14990630.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):37-44 [15162142.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [CommentIn] BMJ. 2009;339:b4691 [19996460.001]
  • (PMID = 19996459.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24 CA 55727; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / 1K12RR023247; United States / NCI NIH HHS / CA / U24 CA055727-17; United States / NCRR NIH HHS / RR / K12 RR023247-05; United States / NCRR NIH HHS / RR / K12 RR023247
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3266843
  •  go-up   go-down


90. Maccormick RE: Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses; 2006;67(2):212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is curative for a small number of malignancies including childhood leukemia, Hodgkin's and non-Hodgkin's lymphoma, and germ cell malignancies.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546325.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


91. Loutfy SA, Fawzy M, El-Wakil M, Moneer MM: Presence of human herpes virus 6 (HHV6) in pediatric lymphomas: impact on clinical course and association with cytomegalovirus infection. Virol J; 2010;7:287
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Activation of herpes virus 6 (HHV6) has seen in Hodgkin's and non-Hodgkin's Lymphoma (HL&NHL) as a result of lymphoma associated immunosuppression.
  • Multiple studies have suggested an association between both HHV6 and cytomegalovirus CMV for development of CMV disease affecting the pathogenesis of lymphoma.
  • Therefore, this study investigated the frequency of HHV6, its impact on clinical manifestations of lymphoma and its possible association with risk for development of CMV infection in pediatric lymphoma patients.
  • CONCLUSION: The presence of HHV6 can be considered as a predicting indicator of cellular immunosuppression preceding the onset of CMV infection which may result in a severe outcome among pediatric lymphoma patients.
  • [MeSH-major] Cytomegalovirus Infections / epidemiology. Herpesvirus 6, Human / isolation & purification. Lymphoma / virology. Roseolovirus Infections / epidemiology

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Virol. 1999 Dec;59(4):496-501 [10534732.001]
  • [Cites] Clin Microbiol Infect. 2008 Dec;14(12):1160-6 [19046167.001]
  • [Cites] Rev Med Virol. 2000 May-Jun;10(3):155-73 [10815027.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):865-70 [10996205.001]
  • [Cites] J Infect Dis. 2001 Jan 1;183(1):130-3 [11076708.001]
  • [Cites] J Infect Dis. 2001 Jan 15;183(2):179-184 [11120923.001]
  • [Cites] Clin Infect Dis. 2001 Feb 15;32(4):539-45 [11181115.001]
  • [Cites] Chest. 2001 Mar;119(3):838-43 [11243966.001]
  • [Cites] FEMS Immunol Med Microbiol. 2003 Mar 20;35(2):125-30 [12628547.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:282-5 [15251973.001]
  • [Cites] Cancer. 1975 Jul;36(1):252-9 [54209.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Science. 1986 Oct 31;234(4776):596-601 [2876520.001]
  • [Cites] Nature. 1987 Sep 17-23;329(6136):207 [3627265.001]
  • [Cites] J Clin Microbiol. 1988 Dec;26(12):2531-5 [2852670.001]
  • [Cites] Clin Microbiol Rev. 1989 Apr;2(2):204-16 [2539899.001]
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1457-76 [2560617.001]
  • [Cites] Blood. 1991 May 15;77(10):2251-8 [1674220.001]
  • [Cites] J Virol. 1991 Sep;65(9):5105-10 [1651426.001]
  • [Cites] Am J Pathol. 1993 Jun;142(6):1714-20 [8506943.001]
  • [Cites] J Clin Pathol. 1993 Dec;46(12):1137-8 [8282842.001]
  • [Cites] J Infect Dis. 1994 Jul;170(1):211-5 [8014502.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1263-71 [7858257.001]
  • [Cites] Virology. 1995 May 10;209(1):29-51 [7747482.001]
  • [Cites] Baillieres Clin Haematol. 1995 Mar;8(1):201-23 [7663047.001]
  • [Cites] Retina. 1996;16(4):324-7 [8865393.001]
  • [Cites] J Med Virol. 1996 Sep;50(1):31-4 [8890038.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1501-10 [8909240.001]
  • [Cites] J Clin Microbiol. 1998 Jan;36(1):68-72 [9431922.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1783-6 [9815234.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):217-45 [15653828.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1213-20 [16078263.001]
  • [Cites] Saudi Med J. 2006 Aug;27(8):1139-45 [16883441.001]
  • [Cites] Microbiol Immunol. 2006;50(10):787-803 [17053315.001]
  • [Cites] Indian J Med Microbiol. 2008 Jan-Mar;26(1):79-80 [18227606.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • (PMID = 20979645.001).
  • [ISSN] 1743-422X
  • [Journal-full-title] Virology journal
  • [ISO-abbreviation] Virol. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2988729
  •  go-up   go-down


92. Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A: CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Eur J Haematol; 2007 Feb;78(2):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
  • Our goal was to optimize use of granulocyte colony-stimulating factor (G-CSF) after high-dose chemotherapy and autologous peripheral blood stem-cell transplantation in lymphoma patients, limiting G-CSF administration to patients infusing a suboptimal CD34(+) cell number.
  • Of 124 consecutive patients with histologically proven Hodgkin's and non-Hodgkin's lymphoma from January 2001 to June 2004, 60 patients (group 1) given > or = 5 x 10(6)/kg CD34(+) cells received no G-CSF; 64 patients (group 2) given < or = 5 x 10(6)/kg CD34(+) cells received G-CSF from day +5 after stem-cell reinfusion.
  • [MeSH-major] Antigens, CD34 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cells / drug effects. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313558.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antifungal Agents; 0 / Antigens, CD34; 0 / Recombinant Proteins; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5V9KLZ54CY / Vinblastine; 6WS4C399GB / lenograstim; PVI5M0M1GW / Filgrastim; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


93. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B: Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol; 2006 Aug 1;24(22):3604-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
  • We reviewed our experience in 526 patients with lymphoma treated by ASCT to determine whether difficult stem-cell harvests predict for an increased risk of t-MDS/AML.
  • Pretransplantation characteristics, including age, diagnosis of non-Hodgkin's lymphoma or Hodgkin's disease, bone marrow involvement, prior radiation therapy, prior exposure to chemotherapy, lactate dehydrogenase at the time of ASCT, disease status, and method of stem-cell mobilization, were then analyzed with respect to the subsequent development of t-MDS/AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Lymphoma / surgery. Myelodysplastic Syndromes / etiology. Peripheral Blood Stem Cell Transplantation


94. Samoszuk M, Kanakubo E, Chan JK: Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer; 2005;5:121
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Degranulating mast cells were localized predominantly in the fibrous tissue of every case of breast cancer, head and neck cancer, lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and Hodgkin's disease that we examined.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Thromb Hemost. 2000;26 Suppl 1:69-77 [11011810.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R274-83 [15987422.001]
  • [Cites] Exp Dermatol. 2001 Jun;10(3):184-92 [11380614.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5562-9 [11454708.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):514-21 [11736931.001]
  • [Cites] Cancer Lett. 2002 Dec 1;186(1):1-9 [12183069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15072-7 [12397176.001]
  • [Cites] J Endocrinol. 2003 Apr;177(1):65-81 [12697038.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):647-52 [12866022.001]
  • [Cites] Thromb Haemost. 2003 Aug;90(2):351-60 [12888884.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):159-63 [12925973.001]
  • [Cites] Pathophysiol Haemost Thromb. 2003;33 Suppl 1:64-6 [12955009.001]
  • [Cites] Pathophysiol Haemost Thromb. 2003;33 Suppl 1:67 [12955010.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):612-21 [14744776.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1261-2 [15304027.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1263-5 [15304028.001]
  • [Cites] J Biol Chem. 1986 Jun 5;261(16):7372-9 [3519608.001]
  • [Cites] Am J Pathol. 1994 May;144(5):862-8 [8178937.001]
  • [Cites] Scand J Immunol. 1994 May;39(5):489-98 [8191224.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Nov 15;204(3):1165-9 [7526860.001]
  • [Cites] Br J Cancer. 1997;75(11):1567-74 [9184170.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):385-8 [9247277.001]
  • [Cites] Thromb Haemost. 1998 Jul;80(1):10-23 [9684778.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):22-36 [9890167.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Nature. 1999 Aug 19;400(6746):773-6 [10466727.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):388-96 [15696191.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2123-9 [15699480.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3772-80 [15867373.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Pharmacol Rev. 2001 Mar;53(1):93-105 [11171940.001]
  • (PMID = 16176582.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / FGF7 protein, human; 126469-10-1 / Fibroblast Growth Factor 7; 15XUH0X66N / Tolonium Chloride; 9005-49-6 / Heparin; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.59 / Tryptases
  • [Other-IDs] NLM/ PMC1242221
  •  go-up   go-down


95. Elbl L, Vasova I, Tomaskova I, Jedlicka F, Kral Z, Navratil M, Smardova L, Wagnerova B, Vorlicek J: Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults. Leuk Lymphoma; 2006 May;47(5):843-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study assessed several parameters of cardiopulmonary function in patients, after treatment for aggressive non-Hodgkin's lymphoma and Hodgkin's disease, to determine the influence of these parameters on patient's performance status.
  • [MeSH-major] Echocardiography, Stress. Exercise Test. Lymphoma / physiopathology. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753868.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


96. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF: Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol; 2006 May;17 Suppl 4:iv25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
  • We have treated 75 transplant-eligible patients with relapsed or refractory lymphoma using an outpatient-based fractionated regimen of ifosfamide, carboplatin and etoposide (ICE) for both salvage and stem cell mobilisation.
  • Patients included DLBC (n = 33), follicular (n = 23), NK/T-cell (n = 3), mantle cell (n = 3) and Hodgkin's lymphoma (n = 13).
  • Most patients with indolent lymphoma also received rituximab.
  • Non-haematological toxicities included grade 1/2 CNS toxicity in four patients, cardiac toxicity in two, reversible renal impairment and haematuria in one each.
  • These data confirm the efficacy and tolerability of outpatient fractionated ICE as both a salvage and mobilisation regimen in relapsed/refractory lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702181.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


97. Mould DR, Sweeney K, Duffull SB, Neylon E, Hamlin P, Horwitz S, Sirotnak F, Fleisher M, Saunders ME, O'Connor OA: A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther; 2009 Aug;86(2):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
  • [MeSH-major] Aminopterin / analogs & derivatives. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Body Size. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Mucositis / prevention & control

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474785.001).
  • [ISSN] 1532-6535
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1UL1RR024156; United States / FDA HHS / FD / R01 FD0003498-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Folic Acid Antagonists; 8LL8S712J7 / Methylmalonic Acid; JYB41CTM2Q / Aminopterin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


98. Serrano D, Miralles P, Balsalobre P, Díez-Martin JL, Berenguer J: Hematopoietic stem cell transplantation in patients infected with HIV. Curr HIV/AIDS Rep; 2010 Aug;7(3):175-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several studies have reported the feasibility, safety, and efficacy of autologous HSCT as rescue or consolidation treatment for non-Hodgkin's and Hodgkin's lymphoma in HIV-infected patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Hodgkin Disease / complications. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods. Treatment Outcome


99. Okamoto R: [Malignant lymphoma]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2532-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma].
  • FDG-PET has technical limitations, variability of FDG avidity among different lymphoma histologic subtypes, and in a large number of etiologies shows false-negative and false positive results.
  • Most studies of FDG-PET involve patients with Hodgkin's disease or diffuse large B-cell lymphoma.
  • FDG PET in lymphoma is being incorporated into the response assessment in lymphoma as published by the Imaging Subcommittee of International Harmonization Project in Lymphoma.
  • New guidelines, the Revised Response Criteria for Malignant Lymphoma, are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009452.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


100. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol; 2007 Feb 10;25(5):579-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revised response criteria for malignant lymphoma.
  • RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma.
  • CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
  • [MeSH-major] Clinical Trials as Topic / standards. Hodgkin Disease / pathology. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242396.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement